Abstract | AIM: PATIENTS AND METHODS: RESULTS: The overall antitumour effect (objective response and stable disease) was 35%; in MTC 42%, in DTC 29%, and in AC 0%. The objective overall response rate was 0%. A stable disease was achieved in 35% (7/20), and progressive disease was found in 65% (13/20). The median time to progression was 8 months, with a median follow-up of 15 months. The treatment was very well tolerated. There were no grade III/IV haematological or renal toxicities. CONCLUSION:
|
Authors | C Waldherr, T Schumacher, M Pless, A Crazzolara, H R Maecke, E U Nitzsche, A Haldemann, J Mueller-Brand |
Journal | Nuclear medicine communications
(Nucl Med Commun)
Vol. 22
Issue 6
Pg. 673-8
(Jun 2001)
ISSN: 0143-3636 [Print] England |
PMID | 11403179
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Radiopharmaceuticals
- Somatostatin
- pentetreotide
- Octreotide
- Edotreotide
|
Topics |
- Adult
- Aged
- Anemia
(etiology)
- Female
- Humans
- Kidney Diseases
(etiology)
- Lymphopenia
(etiology)
- Male
- Middle Aged
- Octreotide
(adverse effects, analogs & derivatives, pharmacokinetics, therapeutic use)
- Pilot Projects
- Radionuclide Imaging
- Radiopharmaceuticals
(adverse effects, pharmacokinetics, therapeutic use)
- Somatostatin
(analogs & derivatives)
- Survival Analysis
- Thyroid Neoplasms
(diagnostic imaging, radiotherapy)
|